Clinical Trials
31 trialsABBY
Abramson Cancer Center at Penn Medicine
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
TAPUR
American Society of Clinical Oncology
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Alliance for Clinical Trials in Oncology
I-SPY
QuantumLeap Healthcare Collaborative
ALEPRO
Universitaire Ziekenhuizen KU Leuven
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
City of Hope Medical Center
ETHAN - ET for Male BC
Dana-Farber Cancer Institute
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
Dana-Farber Cancer Institute
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
University of Washington
ABBICAR
Universitaire Ziekenhuizen KU Leuven
CAMPFIRE
Eli Lilly and Company
Abemaciclib in Newly Diagnosed Meningioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
University of California, Irvine
MiRaDoR
MedSIR
ALPINE: Maintenance Letrozole/Abemaciclib
Dana-Farber Cancer Institute
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
The Methodist Hospital Research Institute
GERTRUDE
Dartmouth-Hitchcock Medical Center
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Dana-Farber Cancer Institute
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Northwestern University
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Jonsson Comprehensive Cancer Center
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
Medical College of Wisconsin
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
University of Texas Southwestern Medical Center
Neo-AGILE
Fondazione Oncotech
FINPROVE
Helsinki University Central Hospital
DRUP
The Netherlands Cancer Institute
ORACLE-RIPA
National Taiwan University Hospital